Retatrutide, also identified in trial registries as LY3437943, is a triple agonist studied at the GIP, GLP-1, and glucagon receptors. The existence of clinical research on a named compound does not establish that a third-party research material is an authorized drug product, equivalent to trial material, or suitable for human use.

Identity starts with the named compound

A procurement record should begin with the compound name, identifiers, molecular information, selected strength, and lot. Those fields help a receiving laboratory reconcile what was ordered with the label and the source document. They do not, by themselves, verify biological activity or authorize a route of use.

Vitatide's canonical Retatrutide product page publishes the specifications and lot-linked analytical fields available for the listed material. Researchers should evaluate those records against their own procurement requirements and validated laboratory SOPs.

What the primary research establishes

A 2023 phase 2 trial publication describes retatrutide as a triple-hormone-receptor agonist and reports the design and outcomes of a randomized clinical study. ClinicalTrials.gov also lists the sponsor's phase 3 TRIUMPH-1 study under identifier NCT05929066. These sources document clinical investigation; they are not instructions for handling commercial research material.

Canadian regulatory context

Health Canada's April 2026 public advisory explicitly lists Retatrutide among unauthorized injectable peptide drugs identified in Canada. The advisory also states that a “For Research Use Only — Not for Human Consumption” label does not make an unauthorized product legal or exempt from regulatory requirements.

Laboratories and purchasers are responsible for determining whether their intended procurement, possession, import, and use comply with applicable requirements. Vitatide's research-use wording is a use boundary, not a claim of regulatory authorization, and this article is not legal or medical advice.

Read the Health Canada public advisory

What a COA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory. Its scope is limited to the sample, methods, and results stated on that document.

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a COA as regulatory approval, sterility assurance, or a substitute for an end laboratory's validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory's responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.